Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): PMS-Timolol (02083345). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Timolol maleate
Form:
16 of 16 products shown
11 general benefit · 5 not a benefit
Timolol Maleate-EX · DIN 02242275 · 0.25% · Oph Gellan Sol
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Timolol Maleate-EX · DIN 02242275
Manufacturer: Alcon Canada Inc.; listing date 2006-08-24
Health Canada: Marketed since 2017-05-19 · brand TIMOLOL MALEATE-EX · ATC S01ED01 TIMOLOL · form Solution (extended-release) · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.25 % · company Sandoz canada incorporated · schedule Prescription
Timolol Maleate-EX: Formulary list price $2.95 per unit (the source does not state the unit; exact figure $2.9540). What the ministry pays, not the patient.
Ministry pays: $2.9540 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02242275: Timolol Maleate-EX
Raw flags: sec3=Y
Item: 523600080; group id 641; item number 1614; lccId None; manufacturer id ALC
Source form: Oph Gellan Sol; strength: 0.25%
Recorded listing: General benefit
Source prices (unrounded): $2.9540; ministry $2.9540
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02242275
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65975
Therapeutic Notes (formulary)
Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.Interchangeable products
Timoptic-XE · DIN 02171880 · not recorded
Shortage status: active shortage (reported May 13, 2024, estimated to end July 30, 2027, last updated February 9, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242275
Shortage record checked October 6, 2026
Sandoz Timolol · DIN 02166712 · 0.25% · Oph Sol
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Sandoz Timolol · DIN 02166712
Manufacturer: Sandoz Canada Inc.; listing date 1999-04-15
Health Canada: Marketed since 2011-06-15 · brand SANDOZ TIMOLOL · ATC S01ED01 TIMOLOL · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.25 % · company Sandoz canada incorporated · schedule Prescription
Sandoz Timolol: Formulary list price $2.35 per unit (the source does not state the unit; exact figure $2.3503). What the ministry pays, not the patient.
Ministry pays: $2.3503 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02166712: Sandoz Timolol
Raw flags: sec3=Y
Item: 523600021; group id 641; item number 1616; lccId None; manufacturer id SDZ
Source form: Oph Sol; strength: 0.25%
Recorded listing: General benefit
Source prices (unrounded): $2.3503; ministry $2.3503
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02166712
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19252
Therapeutic Notes (formulary)
Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.Interchangeable products
Timoptic · DIN 00451193 · not recorded
Shortage status: resolved shortage (ended December 3, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02166712
Shortage record checked October 6, 2026
Timolol Maleate-EX · DIN 02242276 · 0.5% · Oph Gellan Sol
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Timolol Maleate-EX · DIN 02242276
Manufacturer: Alcon Canada Inc.; listing date 2006-08-24
Health Canada: Marketed since 2017-05-19 · brand TIMOLOL MALEATE-EX · ATC S01ED01 TIMOLOL · form Solution (extended-release) · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.5 % · company Sandoz canada incorporated · schedule Prescription
Timolol Maleate-EX: Formulary list price $3.53 per unit (the source does not state the unit; exact figure $3.5320). What the ministry pays, not the patient.
Ministry pays: $3.5320 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02242276: Timolol Maleate-EX
Raw flags: sec3=Y
Item: 523600081; group id 641; item number 1615; lccId None; manufacturer id ALC
Source form: Oph Gellan Sol; strength: 0.5%
Recorded listing: General benefit
Source prices (unrounded): $3.5320; ministry $3.5320
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02242276
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65976
Therapeutic Notes (formulary)
Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.Interchangeable products
Timoptic-XE · DIN 02171899 · $3.5320
Shortage status: active shortage (reported November 17, 2025, estimated to end July 30, 2027, last updated February 9, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242276
Shortage record checked October 6, 2026
Timoptic-XE · DIN 02171899 · 0.5% · Oph Gellan Sol
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Savings card: RxHelp ONE lists Timoptic-XE (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Timoptic-XE · DIN 02171899
Manufacturer: Elvium Life Sciences; listing date 1996-10-01
Health Canada: Marketed since 2020-09-02 · brand TIMOPTIC-XE · ATC S01ED01 TIMOLOL · form Solution (extended-release) · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.5 % · company Elvium life sciences · schedule Prescription
DIN 02171899: Timoptic-XE
Raw flags: sec3=Y
Item: 523600081; group id 641; item number 1615; lccId None; manufacturer id ELV
Source form: Oph Gellan Sol; strength: 0.5%
Recorded listing: General benefit
Source prices (unrounded): $9.3115; ministry $3.5320
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02171899
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18778
Therapeutic Notes (formulary)
Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.Interchangeable products
Timolol Maleate-EX · DIN 02242276 · $3.5320
Shortage status: resolved shortage (ended September 4, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02171899
Shortage record checked October 6, 2026
Jamp-Timolol · DIN 02447800 · 0.5% · Oph Sol
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Timolol · DIN 02447800
Manufacturer: Jamp Pharma Corporation; listing date 2020-06-30
Health Canada: Marketed since 2020-08-20 · brand JAMP-TIMOLOL · ATC S01ED01 TIMOLOL · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.5 % · company Jamp pharma corporation · schedule Prescription
DIN 02447800: Jamp-Timolol
Raw flags: sec3=Y
Item: 523600022; group id 641; item number 1617; lccId None; manufacturer id JPC
Source form: Oph Sol; strength: 0.5%
Recorded listing: General benefit
Source prices (unrounded): $1.2145; ministry $1.2145
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02447800
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93340
Therapeutic Notes (formulary)
Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.Interchangeable products
Apo-Timop · DIN 00755834 · $1.2145
Sandoz Timolol · DIN 02166720 · $1.2145
Timoptic · DIN 00451207 · $1.2145
Shortage status: active shortage (reported September 15, 2026, estimated to end November 27, 2026, last updated September 22, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02447800
Shortage record checked October 6, 2026
Sandoz Timolol · DIN 02166720 · 0.5% · Oph Sol
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Timolol · DIN 02166720
Manufacturer: Sandoz Canada Inc.; listing date 1999-04-15
Health Canada: Marketed since 2011-06-15 · brand SANDOZ TIMOLOL · ATC S01ED01 TIMOLOL · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.5 % · company Sandoz canada incorporated · schedule Prescription
Sandoz Timolol: Formulary list price $1.21 per unit (the source does not state the unit; exact figure $1.2145). What the ministry pays, not the patient.
Ministry pays: $1.2145 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02166720: Sandoz Timolol
Raw flags: sec3=Y
Item: 523600022; group id 641; item number 1617; lccId None; manufacturer id SDZ
Source form: Oph Sol; strength: 0.5%
Recorded listing: General benefit
Source prices (unrounded): $1.2145; ministry $1.2145
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02166720
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19242
Therapeutic Notes (formulary)
Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.Interchangeable products
Apo-Timop · DIN 00755834 · $1.2145
Jamp-Timolol · DIN 02447800 · $1.2145
Timoptic · DIN 00451207 · $1.2145
Shortage status: resolved shortage (ended July 13, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02166720
Shortage record checked October 6, 2026
Timoptic · DIN 00451207 · 0.5% · Oph Sol
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Timoptic · DIN 00451207
Manufacturer: Elvium Life Sciences; listing date 1996-10-01
Health Canada: Marketed since 2020-09-02 · brand TIMOPTIC · ATC S01ED01 TIMOLOL · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.5 % · company Elvium life sciences · schedule Prescription
DIN 00451207: Timoptic
Raw flags: sec3=Y
Item: 523600022; group id 641; item number 1617; lccId None; manufacturer id ELV
Source form: Oph Sol; strength: 0.5%
Recorded listing: General benefit
Source prices (unrounded): $7.2910; ministry $1.2145
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00451207
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3186
Therapeutic Notes (formulary)
Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.Interchangeable products
Apo-Timop · DIN 00755834 · $1.2145
Jamp-Timolol · DIN 02447800 · $1.2145
Sandoz Timolol · DIN 02166720 · $1.2145
Shortage status: resolved shortage (ended December 12, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00451207
Shortage record checked October 6, 2026
Timolol · DIN 00755842 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Timolol · DIN 00755842
Manufacturer: A A Pharma Inc.; listing date 1996-10-01
Daily cost (source): $0.4154
Health Canada: Marketed since 2018-12-12 · brand TIMOLOL · ATC C07AA06 TIMOLOL · form Tablet · route Oral · ingredients TIMOLOL MALEATE 5 MG · company Aa pharma inc · schedule Prescription
DIN 00755842: Timolol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400023; group id 292; item number 0632; lccId None; manufacturer id AAP
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2077; ministry $0.2077
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00755842
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8589Interchangeable products
Blocadren · DIN 00353914 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00755842
Shortage record checked October 6, 2026
Timolol · DIN 00755850 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Timolol · DIN 00755850
Manufacturer: A A Pharma Inc.; listing date 1996-10-01
Daily cost (source): $0.6478
Health Canada: Marketed since 2018-02-27 · brand TIMOLOL · ATC C07AA06 TIMOLOL · form Tablet · route Oral · ingredients TIMOLOL MALEATE 10 MG · company Aa pharma inc · schedule Prescription
DIN 00755850: Timolol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400022; group id 292; item number 0633; lccId None; manufacturer id AAP
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3239; ministry $0.3239
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00755850
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8590Interchangeable products
Blocadren · DIN 00353922 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00755850
Shortage record checked October 6, 2026
Timolol · DIN 00755869 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Timolol · DIN 00755869
Manufacturer: A A Pharma Inc.; listing date 1996-10-01
Daily cost (source): $1.2608
Health Canada: Marketed since 2018-11-01 · brand TIMOLOL · ATC C07AA06 TIMOLOL · form Tablet · route Oral · ingredients TIMOLOL MALEATE 20 MG · company Aa pharma inc · schedule Prescription
DIN 00755869: Timolol
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400043; group id 292; item number 0634; lccId None; manufacturer id AAP
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.6304; ministry $0.6304
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00755869
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8591Interchangeable products
Blocadren · DIN 00495611 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00755869
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Timop · DIN 00755834
Manufacturer: Apotex Inc.; listing date 1996-10-01
Health Canada: Dormant since 2026-01-23 · brand APO-TIMOP · ATC S01ED01 TIMOLOL · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.5 % · company Apotex inc · schedule Prescription
DIN 00755834: Apo-Timop
Raw flags: sec3=Y
Item: 523600022; group id 641; item number 1617; lccId None; manufacturer id APX
Source form: Oph Sol; strength: 0.5%
Recorded listing: General benefit
Source prices (unrounded): $1.2145; ministry $1.2145
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00755834
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8959
Therapeutic Notes (formulary)
Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.Interchangeable products
Jamp-Timolol · DIN 02447800 · $1.2145
Sandoz Timolol · DIN 02166720 · $1.2145
Timoptic · DIN 00451207 · $1.2145
Shortage status: active shortage (reported January 14, 2025, last updated August 28, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00755834
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since January 23, 2026 — choose a marketed DIN from the same-category list.
Timoptic-XE · DIN 02171880 · 0.25% · Oph Gellan Sol
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-10-07 — choose a marketed DIN from the same-category list.Discontinued October 7, 2019 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-10-07 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2019-10-07 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Savings card: RxHelp ONE lists Timoptic-XE (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Timoptic-XE · DIN 02171880
Manufacturer: Purdue Pharma; listing date 1996-10-01
Health Canada: Cancelled post market since 2019-10-07 · brand TIMOPTIC-XE · ATC S01ED01 TIMOLOL · form Solution (extended-release) · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.25 % · company Purdue pharma · schedule Prescription
Timoptic-XE: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 02171880: Timoptic-XE
Raw flags: notABenefit=Y, sec3=Y
Item: 523600080; group id 641; item number 1614; lccId None; manufacturer id PFP
Source form: Oph Gellan Sol; strength: 0.25%
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02171880
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18777
Therapeutic Notes (formulary)
Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.Interchangeable products
Timolol Maleate-EX · DIN 02242275 · $2.9540
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02171880
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since October 7, 2019 — choose a marketed DIN from the same-category list.
Timoptic · DIN 00451193 · 0.25% · Oph Sol
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-11-22 — choose a marketed DIN from the same-category list.Discontinued November 22, 2006 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-11-22 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2006-11-22 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Timoptic · DIN 00451193
Manufacturer: Merck Frosst Canada Ltd.; listing date 1996-10-01
Health Canada: Cancelled post market since 2006-11-22 · brand TIMOPTIC · ATC S01ED01 TIMOLOL · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.25 % · company Merck canada inc · schedule Prescription
DIN 00451193: Timoptic
Raw flags: notABenefit=Y, sec3=Y
Item: 523600021; group id 641; item number 1616; lccId None; manufacturer id MFC
Source form: Oph Sol; strength: 0.25%
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00451193
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3185
Therapeutic Notes (formulary)
Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.
Highest historical DBP for this product is $2.7650.Interchangeable products
Sandoz Timolol · DIN 02166712 · $2.3503
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00451193
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since November 22, 2006 — choose a marketed DIN from the same-category list.
Blocadren · DIN 00353914 · 5 mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-08-03 — choose a marketed DIN from the same-category list.Discontinued August 3, 2000 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-08-03 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2000-08-03 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Blocadren · DIN 00353914
Manufacturer: Merck Frosst Canada & Cie, Merck Frosst Canada & Co.; listing date 1996-10-01
Daily cost (source): $0.4154
Health Canada: Cancelled post market since 2000-08-03 · brand BLOCADREN TAB 5MG · ATC C07AA06 TIMOLOL · form Tablet · route Oral · ingredients TIMOLOL MALEATE 5 MG · company Merck frosst canada & cie, merck frosst canada & co. · schedule Prescription
Blocadren: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 00353914: Blocadren
Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y
Item: 240400023; group id 292; item number 0632; lccId None; manufacturer id FRS
Source form: Tab; strength: 5mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00353914
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3103Interchangeable products
Timolol · DIN 00755842 · $0.2077
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00353914
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 3, 2000 — choose a marketed DIN from the same-category list.
Blocadren · DIN 00353922 · 10 mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-08-03 — choose a marketed DIN from the same-category list.Discontinued August 3, 2000 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-08-03 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2000-08-03 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Blocadren · DIN 00353922
Manufacturer: Merck Frosst Canada & Cie, Merck Frosst Canada & Co.; listing date 1996-10-01
Daily cost (source): $0.6478
Health Canada: Cancelled post market since 2000-08-03 · brand BLOCADREN TAB 10MG · ATC C07AA06 TIMOLOL · form Tablet · route Oral · ingredients TIMOLOL MALEATE 10 MG/TAB · company Merck frosst canada & cie, merck frosst canada & co. · schedule Prescription
Blocadren: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 00353922: Blocadren
Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y
Item: 240400022; group id 292; item number 0633; lccId None; manufacturer id FRS
Source form: Tab; strength: 10mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00353922
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2719Interchangeable products
Timolol · DIN 00755850 · $0.3239
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00353922
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 3, 2000 — choose a marketed DIN from the same-category list.
Blocadren · DIN 00495611 · 20 mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1999-03-02 — choose a marketed DIN from the same-category list.Discontinued March 2, 1999 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1999-03-02 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 1999-03-02 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Blocadren · DIN 00495611
Manufacturer: Merck Frosst Canada & Cie, Merck Frosst Canada & Co.; listing date 1996-10-01
Daily cost (source): $1.2608
Health Canada: Cancelled post market since 1999-03-02 · brand BLOCADREN TAB 20MG · ATC C07AA06 TIMOLOL · form Tablet · route Oral · ingredients TIMOLOL MALEATE 20 MG/TAB · company Merck frosst canada & cie, merck frosst canada & co. · schedule Prescription
Blocadren: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 00495611: Blocadren
Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y
Item: 240400043; group id 292; item number 0634; lccId None; manufacturer id FRS
Source form: Tab; strength: 20mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00495611
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3818Interchangeable products
Timolol · DIN 00755869 · $0.6304
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00495611
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since March 2, 1999 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (C07A, C07AA, S01ED): coverage varies; not interchangeable
Betaxolol (Betoptic S): general benefit
Levobunolol (Betagan): general benefit
Nadolol (Corgard): general benefit, not a benefit
Propranolol (Inderal-LA): general benefit, not a benefit
Sotalol (Sotacor): general benefit, not a benefit
Acebutolol (Sectral): general benefit, not a benefit
15 more in the class list below
Brimonidine tartrate & timolol maleate
All strengths: Limited Use, Reason for Use code 310, 393 required; same patient cost rules
Shared coverage and patient cost rules
StatusLimited Use, Reason for Use code 310, 393 required
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Limited Use, Reason for Use code 310, 393 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 310 or 393 (criteria below)
Ontario Limited Use criteria, code 310, 393
Reason for Use code 310
As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 393
For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Brimonidine-Timop · DIN 02375311
Manufacturer: Apotex Inc.; listing date 2022-12-21
Health Canada: Marketed since 2022-11-09 · brand APO-BRIMONIDINE-TIMOP · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients BRIMONIDINE TARTRATE 0.2 %, TIMOLOL (TIMOLOL MALEATE) 0.5 % · company Apotex inc · schedule Prescription
Apo-Brimonidine-Timop: Formulary list price $23.29 per unit (the source does not state the unit; exact figure $23.2900). What the ministry pays, not the patient.
Ministry pays: $23.2900 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02375311: Apo-Brimonidine-Timop
Raw flags: sec12=Y, sec3=Y
Item: 523600115; group id 615; item number 1582; lccId 00156; manufacturer id APX
Source form: Oph Sol-10mL Pk; strength: 0.2% & 0.5%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $23.2900; ministry $23.2900
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02375311
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86073Interchangeable products
Combigan · DIN 09857298 · $23.2900
Jamp Brimonidine/Timolol · DIN 02531704 · $23.2900
Shortage status: active shortage (reported December 16, 2025, estimated to end January 8, 2027, last updated September 4, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02375311
Limited Use, Reason for Use code 310, 393 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 310 or 393 (criteria below)
Ontario Limited Use criteria, code 310, 393
Reason for Use code 310
As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 393
For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Brimonidine/Timolol · DIN 02531704
Manufacturer: Jamp Pharma Corporation; listing date 2023-08-31
Health Canada: Marketed since 2023-07-21 · brand JAMP BRIMONIDINE/TIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.5 %/W/V, BRIMONIDINE TARTRATE 0.2 %/W/V · company Jamp pharma corporation · schedule Prescription
Jamp Brimonidine/Timolol: Formulary list price $23.29 per unit (the source does not state the unit; exact figure $23.2900). What the ministry pays, not the patient.
Ministry pays: $23.2900 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02531704: Jamp Brimonidine/Timolol
Raw flags: sec12=Y, sec3=Y
Item: 523600115; group id 615; item number 1582; lccId 00156; manufacturer id JPC
Source form: Oph Sol-10mL Pk; strength: 0.2% & 0.5%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $23.2900; ministry $23.2900
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02531704
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102081Interchangeable products
Apo-Brimonidine-Timop · DIN 02375311 · $23.2900
Combigan · DIN 09857298 · $23.2900
Shortage status: active shortage (reported March 12, 2026, estimated to end November 6, 2026, last updated September 21, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02531704
Limited Use, Reason for Use code 310, 393 requiredOntario PIN; no Health Canada record under this code
Write on scriptone applicable Reason for Use code, 310 or 393 (criteria below)
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Health Canada record for this brand: DIN 02248347 (Marketed, 2023-12-13)
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72692
Reason for Use code 310
As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 393
For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Savings card: innoviCares lists Combigan (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Combigan · DIN 09857298
Manufacturer: Allergan Inc.; listing date 2008-08-28
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Health Canada record for this brand: DIN 02248347 (Marketed, 2023-12-13)
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72692
DIN 09857298: Combigan
Raw flags: sec12=Y, sec3=Y
Item: 523600115; group id 615; item number 1582; lccId 00156; manufacturer id ALL
Source form: Oph Sol-10mL Pk; strength: 0.2% & 0.5%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $46.5800; ministry $23.2900
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09857298
Health Canada record for this brand: DIN 02248347 (Marketed, December 13, 2023)
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72692Interchangeable products
Apo-Brimonidine-Timop · DIN 02375311 · $23.2900
Jamp Brimonidine/Timolol · DIN 02531704 · $23.2900
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=09857298
Shortage record checked October 6, 2026
Other products in the same Health Canada class (C07A, C07AA, S01ED): coverage varies; not interchangeable
Betaxolol (Betoptic S): general benefit
Levobunolol (Betagan): general benefit
Nadolol (Corgard): general benefit, not a benefit
Propranolol (Inderal-LA): general benefit, not a benefit
Sotalol (Sotacor): general benefit, not a benefit
Acebutolol (Sectral): general benefit, not a benefit
Limited Use, Reason for Use code 310, 393 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 310, 393 required
Write on scriptone applicable Reason for Use code, 310 or 393 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 310, 393
Reason for Use code 310
As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 393
For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Azarga · DIN 02331624
Manufacturer: Novartis Pharma Canada Inc.; listing date 2010-06-14
Health Canada: Marketed since 2018-03-09 · brand AZARGA · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Suspension · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.5 %/W/V, BRINZOLAMIDE 1 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
DIN 02331624: Azarga
Raw flags: sec12=Y, sec3=Y
Item: 523600131; group id 618; item number 1585; lccId 00204; manufacturer id NOV
Source form: Oph Susp-5mL Pk; strength: 1% & 0.5%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $20.4000; ministry $20.4000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02331624
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81730
Shortage status: resolved shortage (ended April 3, 2020); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02331624
Shortage record checked October 6, 2026
Other products in the same Health Canada class (C07A, C07AA, S01ED): coverage varies; not interchangeable
Betaxolol (Betoptic S): general benefit
Levobunolol (Betagan): general benefit
Nadolol (Corgard): general benefit, not a benefit
Propranolol (Inderal-LA): general benefit, not a benefit
Sotalol (Sotacor): general benefit, not a benefit
Acebutolol (Sectral): general benefit, not a benefit
15 more in the class list below
Dorzolamide HCL & timolol maleate
All strengths: Limited Use, Reason for Use code 310, 393 required; same patient cost rules
Shared coverage and patient cost rules
StatusLimited Use, Reason for Use code 310, 393 required
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Apo-Dorzo-Timop · DIN 02299615 · 2% & 0.5% · Oph Sol
Limited Use, Reason for Use code 310, 393 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 310 or 393 (criteria below)
Ontario Limited Use criteria, code 310, 393
Reason for Use code 310
As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 393
For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Dorzo-Timop · DIN 02299615
Manufacturer: Apotex Inc.; listing date 2011-12-15
Health Canada: Marketed since 2018-06-15 · brand APO-DORZO-TIMOP · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 5 MG/ML, DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20 MG/ML · company Apotex inc · schedule Prescription
Apo-Dorzo-Timop: Formulary list price $2.10 per unit (the source does not state the unit; exact figure $2.0951). What the ministry pays, not the patient.
Ministry pays: $2.0951 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02299615: Apo-Dorzo-Timop
Raw flags: sec12=Y, sec3=Y
Item: 523600098; group id 624; item number 1591; lccId 00087; manufacturer id APX
Source form: Oph Sol; strength: 2% & 0.5%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $2.0951; ministry $2.0951
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02299615
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78499Interchangeable products
Co Dorzotimolol · DIN 02404389 · $2.0951
Cosopt · DIN 02240113 · $2.0951
Dorzolamide-Timolol · DIN 02522020 · $2.0951
Jamp Dorzolamide-Timolol · DIN 02457539 · $2.0951
M-Dorzolamide-Timolol · DIN 02537796 · $2.0951
Med-Dorzolamide-Timolol · DIN 02437686 · $2.0951
Mint-Dorzolamide/Timolol · DIN 02443090 · $2.0951
Riva-Dorzolamide/Timolol · DIN 02441659 · $2.0951
Sandoz Dorzolamide/Timolol · DIN 02344351 · $2.0951
Shortage status: shortage reported ended April 30, 2026 (report last updated April 30, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02299615
Shortage record checked October 6, 2026
Cosopt · DIN 02240113 · 2% & 0.5% · Oph Sol
Limited Use, Reason for Use code 310, 393 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 310 or 393 (criteria below)
Ontario Limited Use criteria, code 310, 393
Reason for Use code 310
As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 393
For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Savings card: RxHelp ONE lists Cosopt (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Cosopt · DIN 02240113
Manufacturer: Elvium Life Sciences; listing date 2000-01-17
Health Canada: Marketed since 2020-08-31 · brand COSOPT · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 5 MG/ML, DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20 MG/ML · company Elvium life sciences · schedule Prescription
DIN 02240113: Cosopt
Raw flags: sec12=Y, sec3=Y
Item: 523600098; group id 624; item number 1591; lccId 00087; manufacturer id ELV
Source form: Oph Sol; strength: 2% & 0.5%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $9.8639; ministry $2.0951
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02240113
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63627Interchangeable products
Apo-Dorzo-Timop · DIN 02299615 · $2.0951
Co Dorzotimolol · DIN 02404389 · $2.0951
Dorzolamide-Timolol · DIN 02522020 · $2.0951
Jamp Dorzolamide-Timolol · DIN 02457539 · $2.0951
M-Dorzolamide-Timolol · DIN 02537796 · $2.0951
Med-Dorzolamide-Timolol · DIN 02437686 · $2.0951
Mint-Dorzolamide/Timolol · DIN 02443090 · $2.0951
Riva-Dorzolamide/Timolol · DIN 02441659 · $2.0951
Sandoz Dorzolamide/Timolol · DIN 02344351 · $2.0951
Shortage status: resolved shortage (ended July 2, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02240113
Shortage record checked October 6, 2026
Dorzolamide-Timolol · DIN 02522020 · 2% & 0.5% · Oph Sol
Limited Use, Reason for Use code 310, 393 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 310 or 393 (criteria below)
Ontario Limited Use criteria, code 310, 393
Reason for Use code 310
As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 393
For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Dorzolamide-Timolol · DIN 02522020
Manufacturer: Jamp Pharma Corporation; listing date 2023-08-31
Health Canada: Marketed since 2023-06-12 · brand DORZOLAMIDE-TIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20 MG/ML, TIMOLOL (TIMOLOL MALEATE) 5 MG/ML · company Jamp pharma corporation · schedule Prescription
Dorzolamide-Timolol: Formulary list price $2.10 per unit (the source does not state the unit; exact figure $2.0951). What the ministry pays, not the patient.
Ministry pays: $2.0951 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02522020: Dorzolamide-Timolol
Raw flags: sec12=Y, sec3=Y
Item: 523600098; group id 624; item number 1591; lccId 00087; manufacturer id JPC
Source form: Oph Sol; strength: 2% & 0.5%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $2.0951; ministry $2.0951
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02522020
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101119Interchangeable products
Apo-Dorzo-Timop · DIN 02299615 · $2.0951
Co Dorzotimolol · DIN 02404389 · $2.0951
Cosopt · DIN 02240113 · $2.0951
Jamp Dorzolamide-Timolol · DIN 02457539 · $2.0951
M-Dorzolamide-Timolol · DIN 02537796 · $2.0951
Med-Dorzolamide-Timolol · DIN 02437686 · $2.0951
Mint-Dorzolamide/Timolol · DIN 02443090 · $2.0951
Riva-Dorzolamide/Timolol · DIN 02441659 · $2.0951
Sandoz Dorzolamide/Timolol · DIN 02344351 · $2.0951
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02522020
Shortage record checked October 6, 2026
M-Dorzolamide-Timolol · DIN 02537796 · 2% & 0.5% · Oph Sol
Limited Use, Reason for Use code 310, 393 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 310 or 393 (criteria below)
Ontario Limited Use criteria, code 310, 393
Reason for Use code 310
As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 393
For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Dorzolamide-Timolol · DIN 02537796
Manufacturer: Mantra Pharma Inc.; listing date 2023-12-29
Health Canada: Marketed since 2023-11-13 · brand M-DORZOLAMIDE-TIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20 MG/ML, TIMOLOL (TIMOLOL MALEATE) 5 MG/ML · company Mantra pharma inc · schedule Prescription
M-Dorzolamide-Timolol: Formulary list price $2.10 per unit (the source does not state the unit; exact figure $2.0951). What the ministry pays, not the patient.
Ministry pays: $2.0951 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02537796: M-Dorzolamide-Timolol
Raw flags: sec12=Y, sec3=Y
Item: 523600098; group id 624; item number 1591; lccId 00087; manufacturer id MAT
Source form: Oph Sol; strength: 2% & 0.5%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $2.0951; ministry $2.0951
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02537796
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102656Interchangeable products
Apo-Dorzo-Timop · DIN 02299615 · $2.0951
Co Dorzotimolol · DIN 02404389 · $2.0951
Cosopt · DIN 02240113 · $2.0951
Dorzolamide-Timolol · DIN 02522020 · $2.0951
Jamp Dorzolamide-Timolol · DIN 02457539 · $2.0951
Med-Dorzolamide-Timolol · DIN 02437686 · $2.0951
Mint-Dorzolamide/Timolol · DIN 02443090 · $2.0951
Riva-Dorzolamide/Timolol · DIN 02441659 · $2.0951
Sandoz Dorzolamide/Timolol · DIN 02344351 · $2.0951
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02537796
Shortage record checked October 6, 2026
Other products in the same Health Canada class (C07A, C07AA, S01ED): coverage varies; not interchangeable
Betaxolol (Betoptic S): general benefit
Levobunolol (Betagan): general benefit
Nadolol (Corgard): general benefit, not a benefit
Propranolol (Inderal-LA): general benefit, not a benefit
Sotalol (Sotacor): general benefit, not a benefit
Acebutolol (Sectral): general benefit, not a benefit
15 more in the class list below
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered
Matched class: 24:04 Cardiac Drugs
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN, PROPAFENONE HCL
Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, AMLODIPINE, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, PROPRANOLOL, SOTALOL HCL, VERAPAMIL HCL
24:00 CARDIOVASCULAR DRUGS
Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered
Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL
Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE
52:36 Other Eye, Ear, Nose and Throat Agents
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
No displayed matched alternative is a general benefit.
BIMATOPROST · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7)
the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular
hypertension
PM: https://pdf.hres.ca/dpd_pm/00049647.PDF; date January 28, 2019; DIN 02429063; fetched 2026-09-10
Product monographBRIMONIDINE · Limited Use, codes 171, 172, 387
the control of intraocular pressure in patients with chronic open-angle glaucoma or ocular
hypertension
PM: https://pdf.hres.ca/dpd_pm/00067621.PDF; date NOV 24, 1997; DIN 02236876; fetched 2026-09-10
Product monographBRINZOLAMIDE · Limited Use, codes 171, 172, 387
• the treatment of elevated intraocular pressure (IOP) in adult patients with ocular hypertension
or open-angle glaucoma.
PM: https://pdf.hres.ca/dpd_pm/00069562.PDF; date OCT 23, 1998; DIN 02238873; fetched 2026-09-10
Product monographLATANOPROST · Limited Use, codes 171, 172, 387
1 INDICATIONS
XALATAN (latanoprost) is indicated for the reduction of intraocular pressure in patients with
open-angle glaucoma or ocular hypertension.
PM: https://pdf.hres.ca/dpd_pm/00077198.PDF; date SEP 25, 2024; DIN 02231493; fetched 2026-09-10
Product monographLATANOPROSTENE BUNOD · Limited Use, codes 171, 172, 387
1 INDICATIONS
VYZULTA™ (latanoprostene bunod ophthalmic solution, 0.024%) is indicated for the reduction
of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
PM: https://pdf.hres.ca/dpd_pm/00048990.PDF; date December 27, 2018; DIN 02484218; fetched 2026-09-10
Product monograph
Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS
TIMOPTIC® (timolol maleate ophthalmic solution, USP) is indicated for:
the reduction of elevated intraocular pressure
1.1 Pediatrics
Pediatrics (<18 years of age): No data are available to Health Canada, therefore, an indication
for pediatric use has not been authorized.
1.2 Geriatrics
Geriatrics (>65 years of age): Evidence from experience in geriatric populations does not
suggests significant differences in safety and effectiveness.
https://pdf.hres.ca/dpd_pm/00067983.PDF
PM date: OCT 28, 2016
Source product: TIMOPTIC; DIN 00451207; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS
APO-BRIMONIDINE-TIMOP (brimonidine tartrate 0.2%/timolol 0.5% (as timolol maleate))
ophthalmic solution is indicated for:
• the control of intraocular pressure (IOP) in patients with chronic open-angle glaucoma or
ocular hypertension who are insufficiently responsive to IOP reducing monotherapy AND
when the use of brimonidine tartrate 0.2%/timolol 0.5% (as timolol maleate) ophthalmic
solution is considered appropriate.
• reduction of long term fluctuation in IOP. In addition to controlling IOP, brimonidine
tartrate 0.2%/timolol 0.5% (as timolol maleate) ophthalmic solution reduces long term
variability, or fluctuation, in IOP. Together, reductions in IOP and in IOP fluctuation are
expected to slow the progression of visual field loss in patients with glaucoma.
1.1 Pediatrics
Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health
Canada has not authorized an indication for pediatric use.
1.2 Geriatrics
Geriatrics (> 65 years of age): Based on evidence from clinical studies and experience, use in
the geriatric population is not associated with any differences…
https://pdf.hres.ca/dpd_pm/00070296.PDF
PM date: December 14, 2022
Source product: APO-BRIMONIDINE-TIMOP; DIN 02375311; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS
AZARGA® (brinzolamide/timolol ophthalmic suspension) is indicated for the reduction of intraocular
pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom
monotherapy provides insufficient IOP reduction and when the use of AZARGA is considered
appropriate.
1.1 Pediatrics (< 18 years of age):
No data are available to Health Canada; therefore, Health Canada has not authorized an indication for
pediatric use.
1.2 Geriatrics (> 65 years of age):
No overall differences in safety and effectiveness have been observed between elderly and other adult
patients.
https://pdf.hres.ca/dpd_pm/00068866.PDF
PM date: DEC 23, 2022
Source product: AZARGA; DIN 02331624; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS
COSOPT® (dorzolamide hydrochloride and timolol maleate) and COSOPT® preservative-free
(without benzalkonium chloride as the preservative) are indicated in the treatment of elevated
intraocular pressure (IOP) in patients with:
• ocular hypertension
• open-angle glaucoma
when concomitant therapy is appropriate.
COSOPT preservative-free is indicated in patients who may be sensitive to a preservative, or
for whom the use of a preservative-free formulation is otherwise advisable. For details please
also refer to the 4 DOSAGE AND ADMINISTRATION section as well as to the 14 CLINICAL TRIALS
section.
1.1 Pediatrics
Pediatrics (<18 years of age): Safety and effectiveness in children have not been established.
No data are available to Health Canada; therefore, an indication for pediatric use has not been
authorized.
1.2 Geriatrics
Geriatrics (>65 years of age): No overall differences in effectiveness or safety were observed
between these patients and younger patients, but greater sensitivity of some older individuals
cannot be ruled out (see 7.1.4 Geriatrics).
https://pdf.hres.ca/dpd_pm/00073687.PDF
PM date: OCT 25, 2016
Source product: COSOPT; DIN 02240113; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS
XALACOM (latanoprost and timolol maleate) is indicated for the reduction of intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are
insufficiently responsive to beta-adrenergic blocking agents, prostaglandins, or other IOP
lowering agents AND when the use of XALACOM (the combination drug) is considered
appropriate.
1.1 Pediatrics
Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health
Canada has not authorized an indication for pediatric use (see 7.1.3 Pediatrics).
1.2 Geriatrics
Geriatrics: Based on the data submitted and reviewed by Health Canada, there is no overall
difference in the safety and efficacy of XALACOM use in the geriatric patient population.
https://pdf.hres.ca/dpd_pm/00071887.PDF
PM date: JUL 21, 2023
Source product: XALACOM; DIN 02246619; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS
DUOTRAV® PQ (travoprost and timolol) is indicated for the reduction of elevated IOP in adult
patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to
beta-blockers, prostaglandins, or other IOP lowering agents AND when the use of DUOTRAV
PQ (the fixed combination drug) is considered appropriate.
DUOTRAV PQ should not be used to initiate therapy.
1.1 Pediatrics
Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health
Canada has not authorized an indication for pediatric use.
1.2 Geriatrics
Geriatics (>65 years of age): No overall differences in safety or effectiveness have been
observed between elderly and other adult patients.
https://pdf.hres.ca/dpd_pm/00059283.PDF
PM date: December 17, 2020
Source product: DUOTRAV PQ; DIN 02278251; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Timolol Maleate-EX · DIN 02242275
Shortage status: active shortage (reported 2024-05-13, estimated to end 2027-07-30, last updated 2026-02-09); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242275
Timolol Maleate-EX · DIN 02242276
Shortage status: active shortage (reported 2025-11-17, estimated to end 2027-07-30, last updated 2026-02-09); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242276
Jamp-Timolol · DIN 02447800
Shortage status: active shortage (reported 2026-09-15, estimated to end 2026-11-27, last updated 2026-09-22); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02447800
Apo-Timop · DIN 00755834
Shortage status: active shortage (reported 2025-01-14, last updated 2026-08-28); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00755834
Apo-Brimonidine-Timop · DIN 02375311
Shortage status: active shortage (reported 2025-12-16, estimated to end 2027-01-08, last updated 2026-09-04); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02375311
Jamp Brimonidine/Timolol · DIN 02531704
Shortage status: active shortage (reported 2026-03-12, estimated to end 2026-11-06, last updated 2026-09-21); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02531704
Apo-Dorzo-Timop · DIN 02299615
Shortage status: shortage reported ended 2026-04-30 (report last updated 2026-04-30); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02299615
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)
Other review policies
For Timoptic-XE, Timoptic, Blocadren: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.